(Q56962426)

4

0 references

Brenda Penninx

3

object named as

Brenda W. Penninx

0 references

Christian Otte

1

object named as

Christian Otte

0 references

author name string

Stefan M Gold

2

0 references

Carmine M Pariante

4

0 references

Amit Etkin

5

0 references

Maurizio Fava

6

0 references

David C Mohr

7

0 references

Alan F Schatzberg

8

0 references

Stefan M. Gold

2

0 references

David C. Mohr

7

0 references

Alan F. Schatzberg

Nature Reviews Disease Primers

8

0 references

language of work or name

English

0 references

publication date

15 September 2016

0 references

published in

0 references

volume

2

0 references

page(s)

16065

0 references

exact match

https://scigraph.springernature.com/pub.10.1038/nrdp.2016.65

0 references

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Cross-national associations between gender and mental disorders in the World Health Organization World Mental Health Surveys

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Cross-national epidemiology of DSM-IV major depressive episode

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Depression and cardiovascular disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Risks of all-cause and suicide mortality in mental disorders: a meta-review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

The genetics of major depression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Maltreatment in childhood substantially increases the risk of adult depression and anxiety in prospective cohort studies: systematic review, meta-analysis, and proportional attributable fractions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

The neural bases of emotion regulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Major depressive disorder: new clinical, neurobiological, and treatment perspectives

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Accumulation of major depressive episodes over time in a prospective study indicates that retrospectively assessed lifetime prevalence estimates are too low

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

How common are common mental disorders? Evidence that lifetime prevalence rates are doubled by prospective versus retrospective ascertainment.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

The epidemiology of depression across cultures

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Use of mental health services for anxiety, mood, and substance disorders in 17 countries in the WHO world mental health surveys

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Common mental disorder severity and its association with treatment contact and treatment intensity for mental health problems

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Natural history of Diagnostic Interview Schedule/DSM-IV major depression. The Baltimore Epidemiologic Catchment Area follow-up

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Two-year course of depressive and anxiety disorders: results from the Netherlands Study of Depression and Anxiety (NESDA).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Interaction between the serotonin transporter gene (5-HTTLPR), stressful life events, and risk of depression: a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Socioeconomic inequalities in depression: a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

The association between lower educational attainment and depression owing to shared genetic effects? Results in ~25,000 subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Current research trends in early life stress and depression: review of human studies on sensitive periods, gene-environment interactions, and epigenetics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Impact of childhood life events and trauma on the course of depressive and anxiety disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Duration of major depressive episodes in the general population: results from The Netherlands Mental Health Survey and Incidence Study (NEMESIS).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Time to recovery, chronicity, and levels of psychopathology in major depression. A 5-year prospective follow-up of 431 subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Global burden of depressive disorders: the issue of duration

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

The four-year course of major depressive disorder: the role of staging and risk factor determination

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

The course of depression in adult outpatients. Results from the Medical Outcomes Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Psychosocial disability before, during, and after a major depressive episode: a 3-wave population-based study of state, scar, and trait effects.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

The burden of major depression avoidable by longer-term treatment strategies.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Understanding the somatic consequences of depression: biological mechanisms and the role of depression symptom profile

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Comprehensive meta-analysis of excess mortality in depression in the general community versus patients with specific illnesses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Genetics and genomics of psychiatric disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Linking the SWI/SNF complex to prostate cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Poor replication of candidate genes for major depressive disorder using genome-wide association data

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

A mega-analysis of genome-wide association studies for major depressive disorder

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Biological insights from 108 schizophrenia-associated genetic loci

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Mental health: depression needs large human-genetics studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Sparse whole-genome sequencing identifies two loci for major depressive disorder

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Identification of 15 genetic loci associated with risk of major depression in individuals of European descent.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Genome-wide analysis of over 106 000 individuals identifies 9 neuroticism-associated loci.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Genetic variants associated with subjective well-being, depressive symptoms, and neuroticism identified through genome-wide analyses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

THE EFFECTS OF STRESSFUL LIFE EVENTS ON DEPRESSION

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Maternal care, gene expression, and the transmission of individual differences in stress reactivity across generations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Depression and hypothalamic-pituitary-adrenal activation: a quantitative summary of four decades of research

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Prenatal stress, development, health and disease risk: A psychobiological perspective-2015 Curt Richter Award Paper

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Effects of perinatal mental disorders on the fetus and child

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Epigenetics of Stress-Related Psychiatric Disorders and Gene × Environment Interactions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Allele-specific FKBP5 DNA demethylation mediates gene-childhood trauma interactions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

The glucocorticoid receptor: pivot of depression and of antidepressant treatment?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Stress hormone regulation: biological role and translation into therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Anna-Monika Award Lecture, DGPPN Kongress, 2013: the role of the hypothalamic-pituitary-adrenal (HPA) axis in the pathogenesis of psychotic major depression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Salivary cortisol in depressed patients versus control persons: a systematic review and meta-analysis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Cognitive impairment in major depression: association with salivary cortisol

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

DST studies in psychotic depression: a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

HPA axis and aging in depression: systematic review and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Recent life events, cortisol, dehydroepiandrosterone and the onset of major depression in high-risk adolescents.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Morning cortisol as a risk factor for subsequent major depressive disorder in adult women

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Suicidal behavior and severe neuropsychiatric disorders following glucocorticoid therapy in primary care

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

The impact of treatment on HPA axis activity in unipolar major depression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Elevated Concentrations of CSF Corticotropin-Releasing Factor-Like Immunoreactivity in Depressed Patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

CRF system and mood disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Antidepressant augmentation with metyrapone for treatment-resistant depression (the ADD study): a double-blind, randomised, placebo-controlled trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Modulation of the mineralocorticoid receptor as add-on treatment in depression: a randomized, double-blind, placebo-controlled proof-of-concept study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Mineralocorticoid receptor stimulation improves cognitive function and decreases cortisol secretion in depressed patients and healthy individuals

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Neuroimmune mechanisms of depression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Autoimmune diseases and severe infections as risk factors for mood disorders: a nationwide study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Neuropsychiatric disorders related to interferon and interleukins treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

A meta-analysis of cytokines in major depression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Cumulative meta-analysis of interleukins 6 and 1β, tumour necrosis factor α and C-reactive protein in patients with major depressive disorder

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Gene expression in major depressive disorder

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Association of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life: a population-based longitudinal study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Serum BDNF concentrations as peripheral manifestations of depression: evidence from a systematic review and meta-analyses on 179 associations (N=9484).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Molecular mechanisms in the regulation of adult neurogenesis during stress.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

The catecholamine hypothesis of affective disorders: a review of supporting evidence

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Research and treatment approaches to depression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Structural neuroimaging studies in major depressive disorder. Meta-analysis and comparison with bipolar disorder

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Subcortical brain alterations in major depressive disorder: findings from the ENIGMA Major Depressive Disorder working group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Cortical abnormalities in adults and adolescents with major depression based on brain scans from 20 cohorts worldwide in the ENIGMA Major Depressive Disorder Working Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Identification of a common neurobiological substrate for mental illness

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Hippocampal atrophy in first episode depression: a meta-analysis of magnetic resonance imaging studies.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Acute Stress Impairs Self-Control in Goal-Directed Choice by Altering Multiple Functional Connections within the Brain's Decision Circuits

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Early-Life Adversity and Physical and Emotional Health Across the Lifespan: A Neuroimmune Network Hypothesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Functional neuroimaging of major depressive disorder: a meta-analysis and new integration of base line activation and neural response data

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Depression, stress, and anhedonia: toward a synthesis and integrated model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Common and Dissociable Dysfunction of the Reward System in Bipolar and Unipolar Depression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

The default mode network and self-referential processes in depression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Resting state networks in major depressive disorder

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Neural correlates of rumination in depression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Default-mode and task-positive network activity in major depressive disorder: implications for adaptive and maladaptive rumination

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Default mode network activity and connectivity in psychopathology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Multi-task connectivity reveals flexible hubs for adaptive task control

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Large-Scale Network Dysfunction in Major Depressive Disorder: A Meta-analysis of Resting-State Functional Connectivity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Reduced caudate and nucleus accumbens response to rewards in unmedicated individuals with major depressive disorder

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Neural systems approaches to understanding major depressive disorder: an intrinsic functional organization perspective

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Current issues in the classification of psychotic major depression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

The NIMH Research Domain Criteria (RDoC) Project: precision medicine for psychiatry

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

US Preventive Services Task Force Recommendation Statement on Screening for Depression in Adults: Not Good Enough

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

There are no randomized controlled trials that support the United States Preventive Services Task Force Guideline on screening for depression in primary care: a systematic review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Preventing the onset of major depressive disorder: a meta-analytic review of psychological interventions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

A review of the current guidelines for depression treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Psychotherapy for depression in adults: A meta-analysis of comparative outcome studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

A meta-analysis of cognitive-behavioural therapy for adult depression, alone and in comparison with other treatments

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Comparative effectiveness of psychological treatments for depressive disorders in primary care: network meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Comparative studies of psychotherapies. Is it true that "everywon has one and all must have prizes"?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Relation of the therapeutic alliance with outcome and other variables: a meta-analytic review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Are all psychotherapies equally effective in the treatment of adult depression? The lack of statistical power of comparative outcome studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Patient predictors of response to psychotherapy and pharmacotherapy: findings in the NIMH Treatment of Depression Collaborative Research Program

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the acute treatment of adults with major depression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Comparative benefits and harms of second generation antidepressants and cognitive behavioral therapies in initial treatment of major depressive disorder: systematic review and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Baseline Depression Severity as Moderator of Depression Outcomes Between Cognitive Behavioral Therapy vs Pharmacotherapy: An Individual Patient Data Meta-analysis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Prevention of relapse following cognitive therapy vs medications in moderate to severe depression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Barriers to psychotherapy among depressed and nondepressed primary care patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Effect of telephone-administered vs face-to-face cognitive behavioral therapy on adherence to therapy and depression outcomes among primary care patients: a randomized trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Group psychological therapies for depression in the community: systematic review and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Behavioral intervention technologies: evidence review and recommendations for future research in mental health.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Computer-based psychological treatments for depression: a systematic review and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Internet and computer-based cognitive behavioral therapy for anxiety and depression in youth: a meta-analysis of randomized controlled outcome trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

MindSpot Clinic: An Accessible, Efficient, and Effective Online Treatment Service for Anxiety and Depression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Trials of Intervention Principles: Evaluation Methods for Evolving Behavioral Intervention Technologies.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Mobile Phone Sensor Correlates of Depressive Symptom Severity in Daily-Life Behavior: An Exploratory Study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Harnessing context sensing to develop a mobile intervention for depression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Initiation and adaptation: a paradigm for understanding psychotropic drug action

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Increasing Adult Hippocampal Neurogenesis is Sufficient to Reduce Anxiety and Depression-Like Behaviors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Molecular and cellular mechanisms of antidepressant action

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Tolerability issues during long-term treatment with antidepressants

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Full central neurokinin-1 receptor blockade is required for efficacy in depression: evidence from orvepitant clinical studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Targeting the inflammatory pathway as a therapeutic tool for major depression.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Evaluation of opioid modulation in major depressive disorder

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

A Phase 1B, randomized, double blind, placebo controlled, multiple-dose escalation study of NSI-189 phosphate, a neurogenic compound, in depressed patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Psychotherapy versus the combination of psychotherapy and pharmacotherapy in the treatment of depression: a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Adding psychotherapy to pharmacotherapy in the treatment of depressive disorders in adults: a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Chronic depression: medication (nefazodone) or psychotherapy (CBASP) is effective when the other is not.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Definition and epidemiology of treatment-resistant depression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Socio-demographic and clinical predictors of non-response/non-remission in treatment resistant depressed patients: A systematic review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Systematic Review and Meta-Analysis: Dose-Response Relationship of Selective Serotonin Reuptake Inhibitors in Major Depressive Disorder

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

A mega-analysis of fixed-dose trials reveals dose-dependency and a rapid onset of action for the antidepressant effect of three selective serotonin reuptake inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Atypical Antipsychotic Augmentation for Treatment-Resistant Depression: A Systematic Review and Network Meta-Analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Cognitive behavioural therapy as an adjunct to pharmacotherapy for primary care based patients with treatment resistant depression: results of the CoBalT randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Long-term effectiveness and cost-effectiveness of cognitive behavioural therapy as an adjunct to pharmacotherapy for treatment-resistant depression in primary care: follow-up of the CoBalT randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

The treatment of chronic depression with cognitive behavioral analysis system of psychotherapy: a systematic review and meta-analysis of randomized-controlled clinical trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Efficacy of ultrabrief pulse electroconvulsive therapy for depression: a systematic review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Repetitive transcranial magnetic stimulation for treatment-resistant depression: a systematic review and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Repetitive transcranial magnetic stimulation versus electroconvulsive therapy for major depression: a systematic review and meta-analysis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Deep transcranial magnetic stimulation as a treatment for psychiatric disorders: a comprehensive review.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Magnetic Seizure Therapy for Unipolar and Bipolar Depression: A Systematic Review.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Repetitive transcranial magnetic stimulation or transcranial direct current stimulation?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Transcranial direct current stimulation (tDCS) in the treatment of depression: Systematic review and meta-analysis of efficacy and tolerability.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Rapid mood-elevating effects of low field magnetic stimulation in depression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Neurostimulation therapies for treatment resistant depression: a focus on vagus nerve stimulation and deep brain stimulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

The Da Vinci Code and the alphabet of research

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

The use of ketamine as an antidepressant: a systematic review and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Omega-3 fatty acid augmentation of citalopram treatment for patients with major depressive disorder.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Antidepressant effects of the muscarinic cholinergic receptor antagonist scopolamine: a review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Opioid Modulation With Buprenorphine/Samidorphan as Adjunctive Treatment for Inadequate Response to Antidepressants: A Randomized Double-Blind Placebo-Controlled Trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Prevalence and effects of mood disorders on work performance in a nationally representative sample of U.S. workers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Cognitive impairment in depression: a systematic review and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

A meta-analysis of the magnitude of biased attention in depression.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

A meta-analysis of cognitive deficits in first-episode Major Depressive Disorder

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Cognitive impairment in euthymic major depressive disorder: a meta-analysis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

A meta-analysis of depression severity and cognitive function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Cognitive markers of psychotic unipolar depression: a meta-analytic study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

The relationship between neurocognitive and psychosocial functioning in major depressive disorder: a systematic review.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

The Cognitive Effects of Antidepressants in Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Suicide and suicidal behaviour

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Direct versus indirect psychosocial and behavioural interventions to prevent suicide and suicide attempts: a systematic review and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Interventions to reduce suicides at suicide hotspots: a systematic review and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Suicidality and aggression during antidepressant treatment: systematic review and meta-analyses based on clinical study reports

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Suicides and Suicide Attempts during Long-Term Treatment with Antidepressants: A Meta-Analysis of 29 Placebo-Controlled Studies Including 6,934 Patients with Major Depressive Disorder

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Expanding the black box - depression, antidepressants, and the risk of suicide

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Antidepressants' black-box warning--10 years later

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Addressing the burden of mental, neurological, and substance use disorders: key messages from Disease Control Priorities, 3rd edition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Epidemiology of major depressive disorder in elderly Nigerians in the Ibadan Study of Ageing: a community-based survey

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

The vascular depression hypothesis: mechanisms linking vascular disease with depression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Association of metabolically healthy obesity with depressive symptoms: pooled analysis of eight studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Metabolic depression: a chronic depressive subtype? Findings from the InCHIANTI study of older persons.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

The role of inflammation in depression: from evolutionary imperative to modern treatment target

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Toward a neuroimaging treatment selection biomarker for major depressive disorder

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Depression Subtypes in Predicting Antidepressant Response: A Report From the iSPOT-D Trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Medicine. Brain disorders? Precisely

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Whither Research Domain Criteria (RDoC)?: The Good, the Bad, and the Ugly

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Development and validation of an international risk prediction algorithm for episodes of major depression in general practice attendees: the PredictD study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Animal models of neuropsychiatric disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Epigenetics of the depressed brain: role of histone acetylation and methylation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Beyond modules and hubs: the potential of gene coexpression networks for investigating molecular mechanisms of complex brain disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Synaptic dysfunction in depression: potential therapeutic targets

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65

Neighborhood matters: divergent patterns of stress-induced plasticity across the brain.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.65